Pharmacophore an International Research Journal
Empagliflozin is a pharmaceutical utilized for the management and treatment of CKD and type 2 DM. Classified under the sodium-glucose co-transporter (SGLT-2) category of diabetes medications, this overview delineates the indications, mechanism of action, and contraindications associated with empagliflozin, underscoring its significance as a valuable therapeutic agent. In the context of diabetic kidney disease, particularly in cases with elevated albuminuria levels, large-scale placebo-controlled trials have demonstrated the efficacy of renin-angiotensin system (RAS) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and the non-steroidal mineralocorticoid receptor antagonist finerenone in reducing the risk of progressing to kidney failure. However, given that the majority of CKD cases globally involve individuals with less lower levels of albuminuria (urinary albumin-to-creatinine ratio [ACR] less than 300 mg/g) and without diabetes, studying a diverse range of CKD patients is of paramount public health importance. The SGLT2 inhibitor dapagliflozin has shown kidney benefits in patients with CKD and a urinary ACR of at least 200 mg/g, even extending to those without diabetes. Studies involving individuals with non-alcoholic fatty liver disease were sought using the following databases; Medline, Pubmed, Embase, NCBI, and Cochrane. The findings suggest that empagliflozin could be a valuable adjunctive therapy in the management of CKD, particularly in populations with diabetes.
